BF Biosciences Launches Zeptide Using IPO Proceeds to Tackle Diabetes in Pakistan

Local Breakthrough in Diabetes and Obesity Treatment

In a significant development for Pakistan’s pharmaceutical industry, BF Biosciences Limited has launched Zeptide (Tirzepatide) — an advanced dual-action therapy for Type 2 diabetes and obesity — developed and produced at its state-of-the-art local manufacturing facility.

The announcement was made in a notice submitted to the Pakistan Stock Exchange (PSX) on Tuesday, underscoring the company’s use of IPO proceeds to fund innovative healthcare solutions within the country.

A Dual-Action Innovation for Diabetes Care

Tirzepatide, approved by the U.S. Food and Drug Administration (FDA), is a synthetic polypeptide that functions as a dual agonist for GLP-1 and GIP receptors. This mechanism offers a groundbreaking approach to managing blood glucose levels while promoting healthy weight reduction — two critical challenges in diabetes management.

The new Zeptide pre-filled syringe, developed at BF Biosciences’ European-technology-based facility, ensures precision, safety, and ease of administration, according to the company.

“With Zeptide, we are proud to bring a world-class therapeutic option to Pakistani patients,” said a company spokesperson. “This innovation reinforces our commitment to developing essential, locally manufactured biologics that meet international quality standards.”

Rigorous Testing and Quality Assurance

BF Biosciences shared that Zeptide underwent comprehensive testing for quality, structure, and potency at a leading biological mass spectrometry facility in the United States and at a national university in Pakistan.

The company emphasized that the project, achieved through IPO proceeds utilization, highlights its dedication to reinvesting in Pakistan’s healthcare ecosystem by introducing advanced biologics and affordable local therapies.

Addressing Pakistan’s Growing Diabetes Burden

With Pakistan ranking among the highest globally in diabetes prevalence, BF Biosciences stressed the urgent need for accessible and effective treatment options.

“Over nine million Pakistanis remain undiagnosed, while 57% of women and 41% of men are overweight or obese — increasing their risk of Type 2 diabetes by up to seven times,” the company noted.

The introduction of Zeptide marks a strategic milestone in the company’s growth trajectory and its mission to address critical, unmet patient needs in Pakistan’s healthcare landscape.

In other news also read about Global Health Warning WHO Sounds Alarm As 1 In 6 Infections Now Resistant To Common Antibiotics